Lung Diseases
70 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: Acute Lung Injury 2, Bronchopulmonary Dysplasia 3, Idiopathic Pulmonary Fibrosis 7, Lung Diseases, Interstitial 18, Pulmonary Arterial Hypertension 4, Pulmonary Disease, Chronic Obstructive 11, Pulmonary Fibrosis 9, Respiratory Distress Syndrome 25
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 16-hour PP for acute lung injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| a wake prone positioning for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Air cleaner for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apremilast for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atibuclimab for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aviptadil for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake prone positioning for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitial | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BC006 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for lung diseases, interstitial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belumosudil 200 mg QD for pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benralizumab for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bersiporocin for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CAL101 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Caspofungin for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenicriviroc for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| clonal fetal MSCs for pulmonary disease, chronic obstructive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CM326 dose 1 + CM326 dose 2 for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for pulmonary fibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 CONVALESCENT PLASMA for lung diseases, interstitial | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclosporine for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CYP Cocktail + ZIPALERTINIB for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyproheptadine for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depemokimab for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone. Dart for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DIAG723 for pulmonary arterial hypertension | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dornase alfa for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EIT-Group for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENDS (Vaporizer/e-cig) and smoking cessation counseling for lung diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Famotidine + Celecoxib for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HB0056 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HSK44459 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for respiratory distress syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine Pill + Azithromycin Pill for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine sulfate for lung diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine Sulfate + Azythromycin for lung diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibuprofen for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Icatibant for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Imatinib Mesylate for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LEAF-4L6715 for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Narsoplimab for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pembrolizumab + lenvatinib for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone decubitus for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for acute lung injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| prone positioning for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rentosertib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for pulmonary arterial hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sildenafil Citrate for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for respiratory distress syndrome | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Taladegib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tozorakimab for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| TQC2731 injection for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transporter Cocktail + ZIPALERTINIB for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treprostinil for pulmonary arterial hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Treprostinil for pulmonary disease, chronic obstructive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treprostinil palmitil for pulmonary arterial hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UC-MSC and Secretome for respiratory distress syndrome | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zipalertinib for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.